Shares of Aptose Biosciences Inc. (NASDAQ:APTO – Get Free Report) (TSE:APS) have earned an average rating of “Buy” from the five research firms that are covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $19.80.
APTO has been the subject of several research reports. Piper Sandler restated an “overweight” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. StockNews.com upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, March 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, March 27th.
Read Our Latest Research Report on Aptose Biosciences
Institutional Inflows and Outflows
Aptose Biosciences Stock Down 3.1 %
APTO opened at $1.23 on Wednesday. The firm has a market cap of $19.33 million, a P/E ratio of -0.16 and a beta of 1.29. Aptose Biosciences has a 52 week low of $1.20 and a 52 week high of $8.70. The business has a fifty day simple moving average of $1.62 and a 200-day simple moving average of $2.16.
Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) last released its earnings results on Tuesday, March 26th. The biotechnology company reported ($1.44) earnings per share for the quarter, beating the consensus estimate of ($1.48) by $0.04. Sell-side analysts expect that Aptose Biosciences will post -3.31 earnings per share for the current year.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
- Five stocks we like better than Aptose Biosciences
- 5 Top Rated Dividend Stocks to Consider
- Comprehensive Analysis of PayPal Stock
- What is the S&P/TSX Index?
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Trading Stocks: RSI and Why it’s Useful
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.